About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

First Line Metastatic Breast Cancer Treatment (ESMERALDA)

NCT01941407·40 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

ARCAGY/ GINECO GROUP

Age

18–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Age \> 18 ans
Patient with metastatic mammary adenocarcinoma
Hormone receptors ER and PR positive or negative for HER 2 negative

You may not be if

Prior chemotherapy for metastatic disease
Previous treatment with eribulin or bevacizumab
Presence of symptomatic brain metastases or meningeal

The record

StatusCompleted

PhasePhase 2

Taking part61

StartedNov 2013

UpdatedMar 17, 2016

Conditions

Metastatic Breast Cancer

Where40

Centre Paul Papin
Angers, France
Centre Hospitalier d'Auxerre
Auxerre, France
Institut Ste Catherine
Avignon, France

Clareo Health | First Line Metastatic Breast Cancer Treatment (ESMERALDA)